Doxorubicin Recruiting Phase 2 Trials for Breast Cancer / Estrogen Receptor-Positive Breast Cancer Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03742986Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
NCT03815890Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO
NCT04038489COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer
NCT02506777Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.
NCT02790580Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients
NCT01176799Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor